Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691056 | 0.91 | GAA (0.55) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL2432659 | 0.90 | ALDH1A1 (0.47) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL2087689 | 0.83 | ALDH1A1 (0.49) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL11158875 | 0.81 | RAB9A (0.55) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL12777001 | 0.81 | ALDH1A1 (0.48) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL2593397 | 0.80 | ALDH1A1 (0.60) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL5673785 | 0.80 | ALDH1A1 (0.60) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL10762630 | 0.77 | PKM (0.58) | ALDH1A1TDP1TSHRPKMCA5A | |
| SCHEMBL5690672 | 0.77 | HSP90AB1 (0.49) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL13000134 | 0.77 | PKM (0.43) | GAAALDH1A1TDP1TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153017-B1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LTD (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-6593354-B2 | Amide substituted benzimidazole or benzoxazole; regulating the interaction of vascular cell adhesion molecule-1 and fibronectin with the integrin vascular cell adhesion molecule very late antigen-4 | AVENTIS PHARMA LIMITED (GB) | 2003-07-15 | — | — | US | disclosed |
| US-20020137782-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-09-26 | — | — | US | disclosed |
| EP-1153017-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | Aventis Pharma Limited (GB) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049005-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LIMITED (GB) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137782-A1 | Substituted bicyclic compounds | ITGA1, VCAM1, ITGB1 | GAA 3668/4885ALDH1A1 157/4885TDP1 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.